A phase 2a, randomized, double-blind 28-day study of TZP-102 a ghrelin receptor agonist for diabetic gastroparesis.

@article{Ejskjaer2013AP2,
  title={A phase 2a, randomized, double-blind 28-day study of TZP-102 a ghrelin receptor agonist for diabetic gastroparesis.},
  author={Niels Ejskjaer and John M. Wo and Tuba Esfandyari and M Mazen Jamal and Georg Dimcevski and Lise Tarnow and Rizwan Abdul Hakim Malik and Per M Hellstr{\"o}m and Elsa Mondou and John F Quinn and Francis Rousseau and R. W. McCallum},
  journal={Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society},
  year={2013},
  volume={25 2},
  pages={e140-50}
}
BACKGROUND Gastroparesis causes significant morbidity and treatment options are limited. TZP-102 a novel, macrocyclic, selective, oral ghrelin receptor agonist, was evaluated in a randomized, double-blind, placebo-controlled trial in patients with diabetic gastroparesis. METHODS A total of 92 outpatients were randomized to once-daily administrations of 10-mg (n = 22), 20-mg (n = 21), 40-mg (n = 23) TZP-102 or placebo (n = 26). The primary endpoint was the change from baseline in gastric half… CONTINUE READING